Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score

Sung Gwe Ahn; Hak Min Lee; Hak Woo Lee; Seung Ah Lee; Se-Ra Lee; Sun-Hee Leem; Joon Jeong; In-Sun Chu
December 2013
International Journal of Molecular Sciences;Dec2013, Vol. 14 Issue 12, p23658
Academic Journal
The Oncotype DX® recurrence score (RS) predictor has been clinically utilized to appropriately select adjuvant chemotherapy for patients with estrogen receptor (ER)-positive early breast cancer. However, the selection of chemotherapy for patients with intermediate RSs remains controversial. We assessed the prognostic value of a 70-gene signature (70GS) among patients with ER-positive breast cancer and intermediate RSs. In addition, we sought to identify genes associated with poor 70GS scores based on gene expression profiling (GEP). GEP was performed using gene expression data from 186 patients with ER-positive breast cancer. The RS and 70GS score were calculated on the basis of GEP. Among 186 patients, 82 ER-positive patients with intermediate RSs were identified. These patients were stratified by 70GS, overall survival (OS) significantly differed according to 70GS (p = 0.013). In a supervised hierarchical analysis according to 70GS, the expression of several representative genes for cell proliferation was significantly higher in the poor 70GS cluster than in the good 70GS cluster. Furthermore, among these patients, FOXM1, AURKA, AURKB, and BIRC5 displayed prognostic significance for OS. In conclusion, 70GS can help to discriminate survival differences among ER-positive patients with intermediate RSs. FOXM1, AURKA, AURKB, and BIRC5, are associated with poor 70GS scores.


Related Articles

  • Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. Loi, Sherene; Haibe-Kains, Benjamin; Desmedt, Christine; Wirapati, Pratyaksha; Lallemand, Françoise; Tutt, Andrew M.; Gillet, Cheryl; Ellis, Paul; Ryder, Kenneth; Reid, James F.; Daidone, Maria G.; Pierotti, Marco A.; Berns, Els M. J. J.; Jansen, Maurice P. H. M.; Foekens, John A.; Delorenzi, Mauro; Bontempi, Gianluca; Piccart, Martine J.; Sotiriou, Christos // BMC Genomics;2008, Vol. 9, Special section p1 

    Background: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to therapies. The ER is currently the best predictor of response to the anti-estrogen agent tamoxifen, yet up to 30-40% of ER+BC will relapse despite tamoxifen...

  • Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. Anderson, H.; Hills, M.; Zabaglo, L.; A'Hern, R.; Leary, A. F.; Haynes, B. P.; Smith, I. E.; Dowsett, M. // Annals of Oncology;Aug2011, Vol. 22 Issue 8, p1770 

    Background: Surprisingly few data are published on the relevance of even commonly used biomarkers of response to aromatase inhibitors (AIs) in advanced breast cancer. Here, we aim to determine the effectiveness of AIs in that setting according to quantitative levels of estrogen receptor (ER),...

  • Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients. Ren, Tingting; Zhang, Jian; Zhang, Jing; Liu, Xinping; Yao, Libo // Medical Oncology;Mar2013, Vol. 30 Issue 1, p1 

    The discoidin domain receptors, DDR1 and DDR2, have been linked with numerous human cancers. We sought to determine expression level and distribution of DDRs in human breast cancer, and investigate prognostic determinates to determine whether levels of DDRs could predict survival. Tumor samples...

  • CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid. Rong-Zong Liu; Garcia, Elizabeth; Glubrecht, Darryl D.; Ho Yin Poon; Mackey, John R.; Godbout, Roseline // Molecular Cancer;2015, Vol. 14 Issue 1, p1 

    Background: Clinical trials designed to test the efficacy of retinoic acid (RA) as an adjuvant for the treatment of solid cancers have been disappointing, primarily due to RA resistance. Estrogen receptor (ER)-negative breast cancer cells are more resistant to RA than ER-positive cells. The...

  • A simple and reproducible prognostic index in luminal ER-positive breast cancers. Castellano, I.; Chiusa, L.; Vandone, A. M.; Beatrice, S.; Goia, M.; Donadio, M.; Arisio, R.; Muscarà, F.; Durando, A.; Viale, G.; Cassoni, P.; Sapino, A. // Annals of Oncology;Sep2013, Vol. 24 Issue 9, p2292 

    Background The group of estrogen receptor (ER)-positive breast cancers (both luminal-A and -B) behaves differently from the ER-negative group. At least in early follow-up, ER expression influences positively patients' prognosis. This low aggressive biology flattens out the differences of...

  • Molecular functions and significance of the MTA family in hormone-independent cancer. Ning, Zhifeng; Gan, Jinfeng; Chen, Chaoying; Zhang, Dianzheng; Zhang, Hao // Cancer & Metastasis Reviews;Dec2014, Vol. 33 Issue 4, p901 

    The members of the metastasis-associated protein (MTA) family play pivotal roles in both physiological and pathophysiological processes, especially in cancer development and metastasis, and their role as master regulators has come to light. Due to the fact that they were first identified as...

  • Is the Oncotype DX Assay Necessary in Strongly Estrogen Receptor-Positive Breast Cancers? LEE, JENNY J.; SHEN, JEANNIE // American Surgeon;Oct2011, Vol. 77 Issue 10, p1364 

    The 21-gene Oncotype DX recurrence score (RS) assay quantifies risk of distant recurrence and predicts benefit from chemotherapy in tamoxifen-treated estrogen receptor (ER)-positive, node-negative breast cancer. Although clinically useful, the assay costs roughly $4650. Because the assay is...

  • Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Cancello, G.; Maisonneuve, P.; Rotmensz, N.; Viale, G.; Mastropasqua, M. G.; Pruneri, G.; Montagna, E.; Iorfida, M.; Mazza, M.; Balduzzi, A.; Veronesi, P.; Luini, A.; Intra, M.; Goldhirsch, A.; Colleoni, M. // Annals of Oncology;Mar2013, Vol. 24 Issue 3, p661 

    Background The immunohistochemical (IHC) evaluation of estrogen receptor (ER), progesterone receptor (PgR), Ki-67 and HER2 is considered a surrogate means for identifying the molecular subtypes of breast cancer with different prognosis. Patients and methods We explored patterns of recurrence in...

  • CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance. Gao, Tian; Han, Yong; Yu, Ling; Ao, Sheng; Li, Ziyu; Ji, Jiafu // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Identification of effective prognostic biomarkers and targets are of crucial importance to the management of estrogen receptor positive (ER+) breast cancer. CCNA2 (also known as CyclinA2) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics